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The human immunodeficiency virus type 1 (HIV-1) genome contains 20 exons that are alternatively spliced from 16 splice
sites to generate more than 40 different mRNAs, including incompletely spliced and unspliced mRNAs. In contrast to avian
retroviral RNA, which has a cis-acting element in gag that negatively regulates splicing (NRS), HIV-1 RNA did not have any
NRS sequences in the gag or pol genes detectable by a splicing inhibition assay. However, this assay demonstrated that
the HIV-1 first 5* splice site competed with a cellular 5* splice site, suggesting that HIV-1 may have some strong splice
sites. To extend this observation, we used a splice site swapping strategy to determine the efficiency of 14 HIV-1 splice
sites in human b globin chimeras tested in transient transfection experiments. While the 1st HIV-1 5* splice site used in
all spliced transcripts and the 4th 5* splice site used in most of the 2-kb transcripts were efficient, the other splice sites,
including all the 3* splice sites, were less efficient, ranging in use from 25 to 60%. We propose that this range of splice
site efficiencies contributes to the regulation of alternative splicing of HIV-1 mRNAs. q 1995 Academic Press, Inc.
INTRODUCTION polyadenylation, transport to the cytoplasm, and transla-
tion. In the case of the simple avian retroviruses, such
Retroviral RNA is transcribed from a provirus inte-
as Rous sarcoma virus (RSV), both the env and the src
grated into the host chromosome and processed by cel-
3* splice sites are suboptimal, but the single 5* splice
lular machinery (reviewed in Coffin, 1990). The capped
site is strong (Berberich and Stoltzfus, 1991; Fu et al.,
and polyadenylated retroviral transcript is alternatively
1991; Katz and Skalka, 1990; McNally and Beemon, 1992;
and incompletely spliced. Mutations that increase splic-
Zhang and Stoltzfus, 1995). Different mechanisms seem
ing decrease viral infectivity, suggesting that a balance
to be involved in inhibition of splicing at the 3* sites. The
of unspliced and spliced transcripts is essential for ret-
RSV env pre-mRNA has a suboptimal branchpoint site
roviral replication (Katz et al., 1988; Zhang and Stoltzfus,
located at 016 nt relative to the 3* splice site and a
1995). The complex genome of human immunodeficiency
suboptimal pyrimidine tract (Fu et al., 1991; Katz et al.,
virus type 1 (HIV-1) (reviewed in Cullen, 1991; Felber and
1988; Katz and Skalka, 1990; Bouck et al., 1995). The src
Pavlakis, 1993) includes 20 exons, bounded by 5 5* and
3* splice site also has a nonconsensus pyrimidine tract
11 3* splice sites, which are alternatively spliced to yield
(Zhang and Stoltzfus, 1995). In addition, a src suppressor
more than 40 transcripts (Felber et al., 1990; Muesing et
of splicing has been identified more than 70 nucleotides
al., 1985; Purcell and Martin, 1993; Robert-Guroff et al.,
upstream of the 3* splice site (Berberich and Stoltzfus,1990; Schwartz et al., 1990). As in the simpler retrovi-
1991; McNally and Beemon, 1992). Splicing is also con-ruses, the 9-kb primary transcript serves as genomic
trolled in RSV by a cis-acting RNA sequence in the gagRNA for progeny virions and as mRNA to generate the
gene termed the negative regulator of splicing (NRS),Gag and Pol proteins. The Env, Vif, Vpr, and Vpu proteins
which decreases splicing at both 3* splice sites (Arrigoare encoded by an 4-kb class of partially spliced
and Beemon, 1988; Stoltzfus and Fogarty, 1989). InsertionmRNAs (Garrett et al., 1991; Schwartz et al., 1990), and
of the NRS into heterologous introns inhibits splicing ina multiply-spliced, 2-kb class of mRNAs encodes the
an orientation- and position-dependent manner in vivoregulatory proteins Tat, Rev, and Nef (Feinberg et al.,
and in vitro (Arrigo and Beemon, 1988; McNally et al.,1986; Felber et al., 1990; Kim et al., 1989).
1991; Gontarek et al., 1993). Thus, multiple cis-actingMaintenance of the proper balance of retroviral
sequences and suboptimal 3* splice sites act additivelymRNAs requires mechanisms that prevent the RNA from
to control splicing of RSV RNA (McNally and Beemon,splicing to completion while still permitting its capping,
1992).
An additional level of complexity exists in HIV where
1 To whom correspondence and reprint requests should be ad-
unspliced and incompletely spliced RNA is not ex-dressed at Department of Biology, Johns Hopkins University, 3400 N.
pressed in the cytoplasm in the absence of a viral-en-Charles Street, Baltimore, MD 21218. Fax: (410) 516-5213. E-mail:
KLB@jhuvms.hcf.jhu.edu. coded regulatory protein, Rev (Emerman et al., 1989;
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Felber et al., 1989; Hammarskjold et al., 1989; Malim and cient splice sites from human b globin. A fragment bear-
ing the 5* or 3* splice site was deleted from constructsCullen, 1993; Malim et al., 1989). Rev binds to a highly
structured RNA sequence, the Rev response element containing the human b globin first intron and replaced
with an HIV-1 fragment bearing a 5* or 3* splice site.(RRE), located in the env gene region that is retained in
both the unspliced and the partially spliced (4 kb) HIV-1 Nine chimeric plasmids containing 14 HIV-1 splice sites
were transfected into 293 cells, and splicing was as-transcripts (Cochrane et al., 1989; Hadzopoulou-Cladaras
et al., 1989; Hauber et al., 1988; Malim et al., 1989; Rosen sayed by RNase protection. We found that the 1st 5*
splice site used in all spliced transcripts and the 4th 5*et al., 1988). Rev regulation requires either inefficient
splicing (Chang and Sharp, 1989; Stutz and Rosbash, splice site used in all but one of the 2-kb transcripts were
efficiently used; however, the other splice sites were not.1994; Lu et al., 1990; Hammarskjold et al., 1994); ele-
ments within gag, pol, and env genes termed cis-acting Thus, a range of splice site efficiencies was observed;
we propose that this contributes to splicing regulation ofrepressive sequences (CRS) (Rosen et al., 1988); inhibi-
tory regions (IR) (Maldarelli et al., 1991); or inhibitory HIV-1 mRNAs.
sequences (Schwartz et al., 1992) or both inefficient splic-
ing and cis-acting repressive sequences. While some MATERIALS AND METHODS
workers observe untranslated CRS-containing RNA in the
Plasmid constructs
cytoplasm in the absence of Rev (Arrigo and Chen, 1991;
Cochrane et al., 1991; D’Agostino et al., 1992), others Sequences from the gag and pol regions of HIV-1 BH10
(Ratner et al., 1986) were tested for their ability to inhibitfound that these RNAs were restricted to the nucleus
(Cochrane et al., 1991; Emerman et al., 1989; Hadzopou- splicing using a heterologous assay developed to study
splicing inhibition by the RSV NRS (Arrigo and Beemon,lou-Cladaras et al., 1989; Hammarskjold et al., 1989;
Maldarelli et al., 1991; Malim and Cullen, 1993). 1988; McNally et al., 1991). HIV-1 fragments containing
IR-1 (BH10 nt 709–2003, where 1 corresponds to theTo investigate the regulation of alternative splicing in
HIV-1, we first asked whether cis-acting sequences anal- beginning of the U3 long terminal repeat (LTR) se-
quence), IR-2 (BH10 nt 2008–3859), and CP490 (BH10 ntogous to the RSV NRS element were present in HIV-1
RNA. Sequences in the gag and pol genes of HIV-1 were 4192–4685) were cloned into a BstXI site within the myc
intron of pRSVNeo-int (Linial, 1987) to generate pNeo-tested for splicing inhibition using a heterologous c-myc
intron splicing assay previously employed to characterize mycIR1, pNeomycIR2, and pNeomycCP490. Additional
constructs were made using subfragments of IR-1: pNeo-the RSV NRS element (Arrigo and Beemon, 1988; McNally
et al., 1991). An HIV-1 gag gene fragment containing a myc3*IR1, (BH10 nt 840–2003) and pNeomyc5*IR1(BH10
nt 708–840). The NRS was contained in an MroI–SphICRS element (IR-1) appeared to inhibit splicing as well
as the NRS; however, the sequences responsible for (RSV nt 706–1006) fragment in pNeomyc(B)MS (McNally
et al., 1991).splicing inhibition by IR-1 mapped to a small 5* fragment
containing the first HIV-1 5* splice site. Unlike the RSV pRSV2Hb was constructed by insertion of the HindIII –
BamHI fragment of plasmid SP64 108 containing the firstNRS which inhibits splicing of the intron it occupies, the
HIV-1 first 5* splice site within IR-1 competed for splicing and second exons and the intervening intron of human
b globin (Reed, 1989; kindly provided by R. Reed) intowith the myc 5* splice site.
Having found that the first HIV-1 splice site was capa- the HindIII and BamHI sites of pRSV2 (McNally et al.,
1991). Transcription of this plasmid initiates in the RSVble of competing with a cellular splice site, we proceeded
to investigate the efficiency of the other HIV-1 splice LTR and is terminated by the simian virus 40 (SV40) early
poly(A) site.sites. Previous studies of the efficiency of HIV-1 splice
sites have involved only a fraction of the 16 identified pHIVHb 5* splice site plasmids. The NcoI–XhoI region
of pRSV2Hb was deleted to remove the human b globinHIV-1 splice sites. Several groups have studied the pair
of splice sites involved in removal of the second intron 5* splice site, together with 94 nt of exon 1 and 77 nt
of adjacent intron sequence. Fragments of HIV-1 BH10of the 2-kb tat/rev mRNAs (Chang and Sharp, 1989;
Krainer et al., 1990; Staffa and Cochrane, 1994), as well sequence containing 5* splice sites were excised from
plasmids pSVGagPol-RRE-R, pSVSX1, or pBH10-flopas the cluster of alternative 3* splice sites used to gener-
ate tat, rev, nef, or vpu/env mRNAs (Amendt et al., 1994; (Smith et al., 1990; Hammarskjold et al., 1989; Rekosh et
al., 1988; all kindly provided by M. L. Hammarskjold).Riggs et al., 1994). However, no global functional compar-
isons have been made between all of the HIV-1 splice After the ends of these fragments were repaired, they
were inserted into pRSV2Hb DNcoI–XhoI to constructsites.
In this study, we investigated the control of alternative the following plasmids: pHIV1Hb, containing the first
HIV-1 5* splice site at nt 740 upstream of the gag genesplicing in HIV-1, using a splice site swapping strategy
to compare the efficiency of 14 HIV-1 splice sites in chim- in the BssHII–XmnI fragment of pSVGagPol-RRE-R (BH10
nt 709–839); pHIV2Hb, containing the second 5* spliceeric substrates. Individual 5* and 3* HIV-1 splice sites
and flanking sequences, as well as two clusters of 3* site at nt 4995 in the AvaII– NdeI fragment of pSVGagPol-
RRE-R (BH10 nt 4971–5158); pHIV3Hb, containing thesplice sites, were tested in vivo in combination with effi-
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third 5* splice site at nt 5486 in the StuI–EcoRI frag- 3* splice site probe template was made by inserting a
332-bp Afl II–PstI fragment from pRSVNeo-int, whichment of pSVGagPol-RRE-R (BH10 nt 5440–5780); and
pHIV5Hb, containing the 4th 5* splice site at nt 6078 spans the myc 3* splice site, into the SmaI site of pGEM-
4Z (Promega). Transcription of the HindIII-cut plasmidin the BsmAI– NdeI fragment of pSVSX1 (BH10 nt
6022–6437). with T7 RNA polymerase yielded a 396-nt probe that
protected bands of 332 and 186 nt, corresponding topHbHIV 3* splice site plasmids. The human b globin
3* splice site, together with 53 nt of intronic sequence unspliced and spliced RNA, respectively. The HIV-1 first
5* splice site probe template was constructed by inser-and 119 nt of exon 2 sequence, was removed from
pRSV2Hb by deleting the XhoI–DraIII fragment. HIV-1 tion of a 130-nt BssHII–XmnI blunted fragment into
pGEM-3Z after the ends were repaired. This plasmid wasBH10 fragments bearing 3* splice sites were blunted and
inserted into pRSV2Hb DXhoI–DraIII to construct the cut with HindIII and transcribed with T7 RNA polymerase
to generate a 191-nt antisense riboprobe. After hybridiza-following plasmids: pHbHIV2, containing the 3* splice
site of exon 2 at nt 4945 in fragment EcoRI–AvaII of tion, a 131-nt unspliced and a 32-nt spliced RNA were
visualized on a 12% polyacrylamide–8 M urea sequenc-pSVGagPol-RRE-R (BH10 nt 4682–4974); pHbHIV3, con-
taining the 3* splice site of exon 3 at nt 5422 in the NdeI– ing gel.
Analysis of globin–HIV chimeric transcripts was car-StuI fragment of pSVGagPol-RRE-R (BH10 nt 5156–5440);
pHbHIV4, containing the 3* splice site of exon 4 at nt ried out by hybridization to an anti-sense transcript of
pHb2, constructed by insertion of the HindIII– BamHI5810 in the StuI– EcoNI (DAvrII– AvrII) fragment of
pSVGagPol-RRE-R (BH10 nt 5438–5825, D5464–5694); fragment of human b globin into the EcoRI–BamHI sites
of pGEM-4Z. pHb2 was linearized by digestion with Hin-pHbHIV4c-5, containing the 3* splice sites of exons 4c,
4a, 4b, and 5 at nt 5969, 5987, 5993, and 6010, respec- dIII and transcribed with SP6 to generate a riboprobe
which spanned the human b globin exon 1–intron 1–tively, in the Sal I– HinfI fragment of pBH10-flop (BH10 nt
5819–6052); and pHbHIV7, containing the 3* splice sites exon 2 region, allowing for the simultaneous detection
of unspliced and spliced RNAs at both the 5* and the 3*of exons 7, 7a, and 7b at nt 8380, 8384, and 8408 in
the HindIII–BamHI fragment of pSVSX1 (BH10 nt human b globin splice sites. A second riboprobe, pMyc2-
3DSal (McNally et al., 1991), was synthesized to detect8172–8509).
expression of the transfection control plasmid, pMyc23.
Cell culture and transfection
RESULTS
The 293 cells, human embryonic kidney cells trans-
formed by human adenovirus type 5 (kindly provided by CRS elements do not affect RNA splicing
G. Ketner), were maintained in minimum essential me-
Unlike viral unspliced RNAs, the unspliced RNAs from
dium with 10% fetal calf serum and penicillin–streptomy-
heterologous genes containing the RSV NRS in the intron
cin. Cells on a 6-cm dish were transfected with 5 mg
are restricted to the nucleus where they accumulate to
plasmid DNA by the calcium phosphate method (Pro-
high levels (Arrigo and Beemon, 1988). This is similar to
mega). To assay for transfection efficiency, the cells were
the nuclear retention observed with the HIV-1 cis-acting
cotransfected with a second plasmid, pMyc23 (McNally
repressive elements and suggested that the RSV and
et al., 1991). Expression of the test plasmids and the
HIV-1 elements may have similar or overlapping activi-
myc plasmids was assayed simultaneously by RNase
ties. To test this, CRS elements from the HIV-1 gag and
protection with different riboprobes.
pol genes were tested for splicing inhibition using a het-
erologous intron splicing assay previously employed toRNA isolation and mapping
characterize the RSV NRS element (Arrigo and Beemon,
1988; McNally et al., 1991).Total cellular RNA was isolated 48 hr after transfection
with RNAzol (Chomczynski and Sacchi, 1987; Cinna/Bio- Three different previously characterized HIV-1 CRS el-
ements (IR-1, IR-2, and CP490) (Maldarelli et al., 1991;tecx). Hybridization and RNase protection were per-
formed as described previously (Arrigo and Beemon, Cochrane et al., 1991) were inserted into the myc intron
of pRSVNeo-int (Linial, 1987) at a position 163 nt down-1988; McNally et al., 1991; Melton et al., 1984) using
probes described below. A PhosphorImager (Molecular stream from the 5* splice site (Fig. 1A). After transfection
of these constructs into 293 cells, the relative amountsDynamics) or InstantImager (Packard) was used to quan-
tify RNA levels, in most cases on 6% polyacrylamide – of spliced and unspliced RNA transcripts were deter-
mined by RNase protection assays, using a probe span-8 M urea sequencing gels (Maxam and Gilbert, 1980).
Adjustments were made for the size and base composi- ning the myc 5* splice site (Fig. 1A). We observed that
control constructs containing no intronic insert producedtion of the respective fragments, when the percentage
of spliced transcripts was calculated. less than 5% unspliced RNA, whereas constructs con-
taining the RSV NRS at this position produced approxi-Riboprobes for analysis of the myc–CRS constructs
included the pRSVNeo-int myc 5* splice site probe, which mately 95% unspliced RNA (Fig. 1B). Similar results
were previously obtained when these constructs werewas described previously (McNally et al., 1991). The myc
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or CP490 inserted into the myc intron (Fig. 1B). However,
levels of unspliced RNA comparable to that generated
with the NRS were seen when IR-1 was present (Fig. 1B).
Control constructs containing these same inserts in the
anti-sense orientation were also tested; none of these
showed an increase in unspliced RNA levels (data not
shown).
To localize the sequences within IR-1 that mediated
splicing inhibition, we tested subfragments of IR-1 in the
myc splicing assay. Using the myc 5* splice site probe,
we found that a 132-nt fragment from the 5* end of IR-1
was as active at inhibiting myc splicing as was either
the entire 1295-nt IR-1 element or the RSV NRS (Fig. 2A).
No inhibition of splicing was seen with a 1163-nt frag-
ment derived from the 3* portion of IR-1 (Fig. 2A). This 5*
IR-1 fragment contains the HIV-1 first 5* splice site that
is used in all spliced HIV-1 transcripts, raising the possi-
bility that the decreased splicing observed from the myc
5* splice site may have resulted from competition be-
tween the myc and the HIV-1 5* splice sites rather than
from the presence of a cis-acting inhibitory element like
the NRS. Since the initial RNase protection assays (Figs.
1B, and 2A) were carried out with a myc 5* splice site
probe, it was not possible to distinguish between these
possibilities. Any splicing of transcripts from the HIV 5*
splice site to the myc 3* splice site would appear as
unspliced RNA using the myc 5* splice site probe, which
is upstream of the HIV-1 insert.
Competition between the myc 5* splice site and the
HIV 5* splice site within IR-1
To determine if the unspliced RNA observed in the
presence of IR-1 resulted from splicing inhibition or com-
petition between the myc 5* splice site and the site in
IR-1, additional RNase protection assays were performed
using probes for both myc 5* and myc 3* splice sites and
for the HIV-1 5* splice site. If splicing were inhibited, aFIG. 1. Test of splicing inhibition of a heterologous intron by HIV-1
CRS elements. (A) Schematic diagram of the HIV-1 genome, showing similar high amount of protected probe corresponding to
a blowup of the gag–pol region indicating the location of the three CRS unspliced RNA would be present with both myc splice
elements used in this study. IR-1 and IR-2 were defined by Maldarelli et site probes. In contrast, competition for splicing by the
al. (1991) and CP490 was defined by Cochrane et al. (1991). Each of
HIV-1 5* splice site would result in higher levels of fullythe CRS elements was inserted into the myc intron of the pRSVNeo-
protected probe (apparent unspliced RNA) using the mycint construct (Linial, 1987) at a site 167 nt from the 5* splice site. The
relative positions of the RNase protection probe and the two digestion 5* splice site probe than with the myc 3* splice site probe.
products are shown. Open boxes represent neo sequences, black When RNA from 293 cells transfected with RSV NRS-
boxes the myc exon sequences flanking the myc second intron (thin containing constructs was analyzed, the 5* and 3* myc
line), and stippled boxes depict SV40 sequences surrounding the small
splice site probes both protected a substantial amountt intron. (B) RNase protection analysis of RNA from 293 cells transfected
of unspliced RNA, as expected from a general splicingwith pRSVNeo-int and its derivatives. RNA from the parental pRSVNeo-
int construct is in the insert lane marked None. The other lanes indicate defect, and probes specific for the NRS indicated no
the fragment inserted into the myc intron in the sense orientation. The splicing within the NRS itself (data not shown). With the
3* IR-1 insert is a truncated derivative of IR-1, lacking 130 nt at the 5* IR1 and 5*IR1 constructs, the myc 5* splice site probe
end. The positions of protected fragments representing unspliced (602
generated substantial signal representing unsplicednt) and spliced (441 nt) RNA are indicated at the left.
RNA (Fig. 2A), but the 3* splice site probe suggested
splicing was nearly complete (Fig. 2B). This is consistent
with efficient splicing occurring between the myc 3*transfected into chicken embryo fibroblasts (McNally et
al., 1991). No inhibition of splicing was detected with splice site and another 5* splice site, most likely that in
the 5* end of the HIV IR-1 construct. This interpretationconstructs containing the pol gene CRS elements IR-2
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FIG. 2. The 5* splice site within HIV-1 IR-1 competes with the myc 5* splice site in pRSVNeo-int. The RNA and probes used in RNase protection
assays to assess use of the first HIV 5* splice site in a heterologous construct are illustrated at the top. Probes flanking the three splice sites are
shown beneath the RNA diagram. Potential splicing from either the myc or the HIV 5* splice site is depicted by lines connecting each to the myc
3* splice site. (A) RNase protection assay of RNA from transfected 293 cells using a myc 5* splice site probe, as described in Fig. 1. Protected
RNAs were resolved on a 6% polyacrylamide–8 M urea gel. The lane labeled myc contains the parental pRSVNeo-int construct. IR1 contains the
entire HIV-1 IR-1 fragment inserted into the intron of pRSVNeo-int as described in Fig. 1. 3* IR1 contains the 3*-terminal portion of IR-1 (nt 840–
2003); 5*IR1 contains the 5*-terminal portion of IR-1 (nt 708–840), including the first HIV-1 5* splice site. (B) RNAs from (A) were also analyzed with
a myc 3* splice site probe. The myc 3* splice site probe is 396 nt and protects 332- and 167-nt fragments representing unspliced and spliced RNA,
respectively. M lane contains markers. (C) RNAs from (A) were also analyzed with a HIV-1 5* splice site probe. The HIV-1 5* splice site probe is
191 nt, and protects 131- and 32-nt spliced bands. These bands were resolved on a 12% polyacrylamide–8 M urea gel.
was tested by RNase protection analysis with a probe these splice sites to one another, a set of chimeric con-
structs containing 14 HIV-1 splice sites paired with hu-specific for the HIV-1 first 5* splice site; this probe
showed high levels of spliced RNA with both the IR1 and man b globin splice sites was generated, and the splic-
ing efficiencies of these constructs were compared inthe 5*IR1 constructs (Fig. 2C). In conclusion, none of the
three CRS elements tested inhibited splicing, and the transfected cells.
The nucleotide positions of the HIV-1 BH10 splice sitesfirst HIV 5* splice site competed efficiently with the myc
5* splice site in these constructs. were determined by comparison of the BH10 sequence
(Ratner et al., 1986) to that of HIV-1 HXB2 splice sites
(Schwartz et al., 1990, 1991) and to the splice sites ofFourteen HIV-1 splice sites assayed in chimeric
pNL4-3 in the case of 3* splice site 4c (Purcell and Martin,constructs
1993). In all cases, the BH10 splice junctions were identi-
The HIV-1 genome contains 20 exons, which are alter- cal in sequence to those of HXB2. Table 1 displays a
natively spliced using 16 splice sites, shown in Fig. 3, to comparison of the HIV-1 BH10 splice site sequences to
generate more than 40 different transcripts (Felber et al., consensus splice sites (Senapathy et al., 1990). While all
1990; Muesing et al., 1985; Purcell and Martin, 1993; of the 5* splice sites match the consensus sequence by
Robert-Guroff et al., 1990; Schwartz et al., 1990). To ex- 6 to 8 of 9 nucleotides, none of the 3* splice sites are
tend the observation that the first HIV-1 5* splice site is good matches to the consensus because their pyrimidine
very strong (Fig. 2C), we investigated the relative tracts are very short and interrupted by purines. Since
none of the HIV-1 branchpoints have been identified ex-strengths of the other HIV-1 splice sites. To compare
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FIG. 3. HIV-1 BH10 genome organization. (A) Open reading frames. (B) Splice sites. BH10 splice sites were determined by sequence comparison
to splice sites identified in HXB2 and pNL4-3 (Purcell and Martin, 1993; Schwartz et al., 1990, 1991). The locations of the 5* splice sites are indicated
above and of the 3* splice sites below the diagram. 5* splice site 5 is used by multiple exons, containing 3* splice sites 3–5.
perimentally and these can be as far as 100 nt upstream and intron and most of the second exon (Reed, 1989)
into the pRSV2 expression vector (McNally et al., 1991),of the 3* splice sites (reviewed in Smith et al., 1989), we
have not tried to match putative branchpoints to the so that transcription of this plasmid initiates in the RSV
long terminal repeat and is terminated by the SV40 earlybranch consensus sequence.
To examine the efficiency of individual HIV-1 splice polyadenylation signal (lacking any SV40 intron). The
sites in vivo, a splice site swapping strategy was used second b globin exon was truncated at its 3* end by 14
in which a fragment containing a 5* or 3* HIV-1 splice nt in this construct to avoid the inclusion of the 5* splice
site was paired with an efficient splice site from human site of exon 2 upstream of the polyadenylation site; this
b globin. The parental b globin construct, pRSV2Hb, has been shown to interfere with the definition of the
shown in Fig. 4, was constructed by the insertion of hu- ultimate exon and polyadenylation in other constructs
man b globin sequence spanning the entire first exon assayed in vivo (Niwa et al., 1992).
To generate chimeric splicing substrates, a fragment
containing the 5* or 3* splice site of human b globin was
TABLE 1
deleted from pRSV2Hb and an HIV-1 fragment bearing
Comparison of HIV-1 BH10 Splice Site Sequences with Consensus a 5* or 3* splice site was inserted in its place (Fig. 4).
Sequence Splice Sitesa Four HIV-1 5* splice site/b globin chimeric plasmids
were constructed after the globin 5* splice site, together5* splice site Sequence
with 94 nt of exon 1 and 77 nt of intron 1, was deleted.
Consensus (C/A)AG/GT(A/G)AGT So that the splice sites are in their normal, viral context,
HIV1Hb CTG/GTGAGT each 5* HIV-1 splice site chimeric construct contained
HIV2Hb AAG/GTGAAG
from 24 to 56 nt of adjacent HIV-1 exonic sequence andHIV3Hb AAG/GTAGGA 90 nt of intronic sequence. For example, a 130-nt se-HIV5Hb GCA/GTAAGT
quence including the first HIV-1 5* splice site, containing
3* splice site Sequence
31 nt of exon 1 and 99 nt of adjacent intron, was substi-
tuted for the globin 5* splice site and flanking sequencesConsensus (Py)nN(C/T)AG/G
HbHIV2 GGGTTTATTACAG/G to generate pHIV1Hb. Similarly, fragments bearing the
HbHIV3 GACTGTTTTTCAG/A 5* splice site regions of splice sites 2 and 3 (Fig. 3B)
HbHIV4 TATCCATTTTCAG/A were used to generate pHIV2Hb and pHIV3Hb, respec-
HbHIV4c TTTCATTGCCAAG/T
tively. The 5* splice site region 5 cloned into pHIV5HbHbHIV4a TTCATAACAAAAG/C
was used in a number of different exons with alternativeHbHIV4b AACAAAAGCTTAG/G
HbHIV5 TCTCCTATGGCAG/G 3* splice sites, including 3, 4, 4c, 4a, 4b, and 5 (Fig. 3B).
HbHIV7a TGAATAGAGTTAG/G Five b globin/HIV-1 3* splice site chimeric plasmids
HbHIV7b TAGAGTTAGGCAG/G
were also constructed. As with the 5* splice site HIVHbHbHIV7 ATTATCGTTTCAG/A
plasmids, the numbers in the names correspond to the
a Nucleotides which match the consensus are underlined. numbers of the splice sites shown in Fig. 3B. pHbHIV2
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total RNA was isolated 48 hr after transfection. RNase
protection assays were performed using an anti-sense
riboprobe that was complementary to human b globin
exons 1 and 2, as well as the intervening intron 1,
allowing unspliced and spliced transcripts using either
splice site to be distinguished by gel electrophoresis
(Figs. 5 and 6). Thus, this same probe could be used to
assay the splicing efficiency of all nine chimeras,
allowing direct comparisons between them without varia-
tions due to the use of different probes. Multiple transfec-
tion experiments were performed, and the splicing level
of each construct was quantified. Table 2 displays the
average percentage of spliced RNA obtained with each
construct.
The HIV-1 5* splice sites of exons 1 and 5 are used
efficiently
The transcripts generated by the control plasmid,
pRSV2Hb, were spliced quite efficiently (89 { 12%
spliced) as expected (Fig. 6, Table 2). However, the
HIV1Hb transcript bearing the first HIV-1 5* splice site,
upstream of the gag coding region, was spliced even
more efficiently (95 { 4% spliced) than the human b
globin first 5* splice site. We have observed similar re-
sults with a second HIV1Hb construct containing 264 nt
of additional HIV-1 exonic sequence upstream of the 5*
FIG. 4. Plasmid constructs. (A) pRSV2Hb. The human b globin exon splice site, extending to include the authentic HIV-1 RNA
1–intron 1– exon 2 region was inserted into the expression vector 5* terminus (C. T. O’Sullivan and K. L. Beemon, unpub-
pRSV2 such that transcription initiates in the RSV LTR and is terminated
lished results). This suggests that there are no inhibitoryby the SV40 poly(A) site. (B) pHIVHb 5* splice sites. The human b
elements upstream of this 5* splice site that are activeglobin 5* splice site region was deleted from pRSV2 and replaced with
in 293 cells. These results extend and confirm our earliera 5* splice site region from HIV. The numbers in the plasmid names
refer to the splice sites, numbered as in Fig. 3. Also indicated are the finding of a strong first 5* splice site, based on splice
transcripts generated by use of that splice site. (C) pHbHIV 3* splice site competition experiments in a construct with two 5*
site plasmids. The b globin 3* splice site region was deleted from
splice sites (Fig. 2C). In that experiment, differentpRSV2Hb and replaced with a 3* splice site from HIV.
amounts of HIV-1 downstream intronic sequence (100 to
1263 nt) in constructs 5*IR1 and IR1 did not affect usage
of this 5* splice site, suggesting that neither upstreamand pHbHIV3 include sequences bearing the 3* splice
sites of exons 2 and 3, respectively. The fragment cloned nor downstream sequences regulate its activity. This
splice site, which is used in all the spliced mRNAs, exhib-into the pHbHIV4 plasmid contains the 3* splice site of
exon 4. The plasmid pHbHIV4c-5 includes the 3* splice its the closest match to a consensus 5* splice site (8/9
nt, including all of the intronic nt) of all the HIV-1 splicesites of exons 4c, 4a, 4b, and 5 that are clustered within
a 41-nt region. Because 3* splice sites include significant sites (Table 1). The presence of an efficient first 5* splice
site in HIV-1 reiterates the finding of a strong 5* spliceupstream intronic sequence (branchpoint and pyrimidine
tracts) which would overlap with these splice sites, it site in avian retroviruses (Katz and Skalka, 1990; McNally
and Beemon, 1992).was not possible to separate them. For the same reason,
three 3* splice sites, 7, 7a, and 7b, that are clustered The 5* splice site in pHIV5Hb, which is used in multiple
mRNAs to remove the intron nearest the 3* end of thewithin a 28-nt region, were cloned into pHbHIV7. Be-
cause exon 6D is used infrequently (Benko et al., 1990; RNA to generate the 2-kb class of HIV-1 mRNAs (tat, rev,
nef ), was 83 { 10% spliced (Fig. 6, Table 2). It may bePurcell and Martin, 1993), we chose not to investigate
its splice sites. Since none of the HIV-1 branchpoints significant that this splice site is not as strong as the
first 5* splice site, since many HIV-1 mRNAs are singlyhave been mapped, enough intronic sequence (100 nt)
was included in the HIV-1 3* splice site constructs to spliced, and all of these have spliced out only the first
intron. Thus, the 4-kb class of HIV-1 mRNAs all use thecontain any distant branchpoints.
To analyze the splicing efficiency of the chimeric HIV- first 5* splice site and do not use the second major 5*
splice site at nt 6078. The HIV-1 5* splice sites 2 (38 {1/human b globin transcripts in vivo, the constructs were
transfected into 293 cells with calcium phosphate, and 11% spliced) and 3 (45 { 6% spliced) of exons 2 and 3,
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FIG. 5. Probes used for RNase protection assay. Linearized pGEM4ZHb2 was used as a template for the synthesis of a riboprobe which spanned
both b globin intron 1 splice sites. The sizes of unspliced and spliced pRSV2Hb, HIVHb, or HbHIV fragments protected by this probe are indicated.
which are present in the 2-kb transcripts as optional, DISCUSSION
upstream, noncoding exons, were less efficiently used The HIV-1 primary RNA transcript is used in its un-
in the hybrid transcripts than were the 5* splice sites spliced form as mRNA and genomic RNA; it is also a
1 or 5. pre-mRNA that is alternatively spliced to generate more
than 40 different mRNAs. As an initial step in dissecting
All the HIV-1 3* splice sites are suboptimal
the mechanisms involved in this very complex splicing
pathway, we have compared the relative efficiencies ofThe levels of splicing observed with the HIV-1 3* splice
site chimeric constructs were also variable (Fig. 6, Table the HIV-1 splice sites in the absence of viral proteins
and have searched for cis-acting splicing regulatory se-2). The 3* splice site 2 was the least efficiently used of
all the splice sites (26 { 16% spliced). Splicing to this quences in the HIV-1 gag and pol genes. In contrast to
previous conclusions that HIV-1 splice sites are subopti-site is necessary to generate the 4-kb vif mRNA. Exon 2,
bordered by 3* splice site 2 and 5* splice site 2, is also mal, based on analysis of a subset of these splice sites,
we have observed that the first 5* splice site is verypresent as a noncoding exon in many 2-kb mRNAs. A
higher level of spliced RNA was obtained with 3* splice strong in several different contexts. Further, the 5* splice
site used to generate the 2-kb mRNAs is relatively strong,site 3 (60 { 10% spliced), which is used to generate the
4-kb vpr mRNA and is also used, in conjunction with 5* but weaker than the first 5* splice site. However, all of
the 3* splice sites are suboptimal (60% splicing); thus,splice site 3, as an optional, noncoding exon of the 2-kb
mRNAs. HbHIV4 RNA, containing the first tat 3* slice site, there are no strong pairs of splice sites in HIV-1 pre-
mRNA. Comparison of the relative strengths of splicewas spliced at an intermediate level (55 { 11% spliced).
Despite bearing multiple 3* splice sites from exons 4c, sites of HIV-1 and RSV RNAs showed striking similarities,
in that both have strong 5* splice sites and weaker 3*4a, 4b, and 5 (for rev, nef, env, and vpu), pHbHIV4c-5
transcripts (48 { 11% spliced) were spliced with slightly splice sites (Fig. 7).
Comparison of the relative efficiencies of 14 HIV-1lower efficiency. The level of splicing obtained with
pHbHIV7 transcripts, which contain the 3* splice sites of splice sites in globin chimeric constructs showed consid-
erable variation. Transcripts containing HIV-1 5* splicetat, rev, and nef 3*-terminal exons, was even lower (41
{ 11% unspliced). Since HbHIV7 contains three alterna- sites ranged from 38 to 95% spliced, while the HIV-1 3*
splice site transcripts varied from 26 to 60% spliced. Wetive 3* splice sites (7, 7a, and 7b) but only use of splice
site 7 results in functional mRNAs (Schwartz et al., 1990), propose that this inherent variability in the efficiency of
the HIV-1 splice sites contributes to the control of alterna-the level of splicing to 7 is lowered due to competition
between these three splice sites, which are present in tive splicing in HIV-1. In most cases, the efficiency of use
of a splice site in the chimeric transcript correlated witha 28-nt region. In contrast to the HIV-1 5* splice sites,
none of the 3* splice sites yielded more than 60% spliced that splice site’s usage in HIV-infected cells, as deter-
mined by the relative abundance of transcripts containingRNA. Therefore, in HIV-1 there are no possible combina-
tions of strong 5* and 3* splice sites that can be used that splice site (Guatelli et al., 1990; Purcell and Martin,
1993; Robert-Guroff et al., 1990). The most efficient splicetogether.
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FIG. 6. Splicing efficiency of chimeras assessed by RNase protection assays. RNase protection analysis was performed on total RNA from 293
cells transfected with the parental human b globin construct, pRSV2Hb (lane 3); with the 5* HIV splice site constructs, pHIVHb (lanes 4–7); or with
3* HIV splice site constructs, pHbHIV (lanes 9–13), using the Hb2 riboprobe to distinguish unspliced from spliced RNA. Lane 1 contains the b
globin riboprobe. The b globin riboprobe protected two spliced bands representing both exons of pRSV2Hb (lane 3) and is therefore a control for
both HIVHb and HbHIV splicing. Multiple-spliced bands, all of which were quantified together, were observed with all of the HbHIV transcripts
(lanes 9–13) and also with the globin control (lane 3). The amount of total RNA recovered after RNase protection with construct HIV2Hb (lane 5)
was reproducibly less than with the other constructs, possibly due to instability of this chimeric RNA. The band showing the control for transfection
efficiency was cut off of the bottom of this gel. From the top of the gel, the sizes of the HpaII DNA marker bands are 622, 527, 404, 309, 242, 238,
217, 180, 160, and 123 nt (lane 2).
site, the first 5* splice site, is used in all spliced tran- ducibly lower than the others. This may reflect differ-
ences in the stability of the transcripts. If degradationscripts. The second most efficient was the 5* splice site
used in all of the 2-kb transcripts encoding Tat, Rev, and occurs prior to splicing or affects spliced and unspliced
transcripts similarly, this would have no effect on theNef. The 3* splice sites of exon 7, also used in these 2-
kb transcripts, were less efficiently used than the 5* levels of splicing observed. However, a difference in the
stability of the spliced and unspliced transcripts wouldsplice site, consistent with previous studies (Chang and
Sharp, 1989; Staffa and Cochrane, 1994). The infrequently alter the interpretation of splicing levels. Additional work
is needed to determine the relative stabilities of HIV-1used exons 2 and 3 had relatively weak splice sites;
these exons had the poorest 5* splice sites, and exon 2 mRNAs. It is interesting that Rev has been observed to
increase the stability of incompletely spliced RRE-bear-also had the poorest 3* splice site (26% spliced), in con-
trast exon 3 had a relatively strong 3* splice site (60% ing HIV-1 transcripts (Felber et al., 1989; Malim and Cul-
len, 1993).spliced).
Some variation in total RNA levels was observed be- As in the simple avian retroviruses previously studied
(Katz and Skalka, 1990; McNally and Beemon, 1992), thetween the different chimeric transcripts shown in Fig. 6.
In particular, the level of HIV2Hb transcripts was repro- 5* splice site nearest the 5* end of HIV-1 RNA was highly
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TABLE 2 for stability and Rev-dependent expression of HIV-1 env
mRNAs.Average Percentage Spliced RNAs of the
The 3* splice sites of the avian retroviruses are bothHIV-1/Human b Globin Construct
suboptimal (Berberich and Stoltzfus, 1991; Fu et al.,
Construct Average SD N 1991; Katz and Skalka, 1990; McNally and Beemon,
1992; Zhang and Stoltzfus, 1995). The 3* splice sites of
RSV2Hb 89 12 7
HIV-1 were also suboptimally spliced to a comparableHIV1Hb 95 4 7
level as shown in Fig. 7. The competing 3* splice sitesHIV2Hb 38 11 8
HIV3Hb 45 6 8 (4, 4c, 4a, 4b, and 5) used in tat, rev, nef, and vpu/env
HIV5Hb 83 10 6 transcripts are closely spaced within a 200-nt region.
HbHIV2 26 16 7 Chimeric pHbHIV4 transcripts bearing the 3* splice
HbHIV3 60 10 7
site nearest the 5* end of this cluster that is used inHbHIV4 55 11 8
tat transcripts were 55% spliced in our assays. How-HbHIV4c-5 48 11 7
HbHIV7 41 11 7 ever, in the viral context this splice site is down-regu-
lated by a splicing regulatory element (SRE) (Amendt
Note. N indicates number of transfections. et al., 1994), which is not present in our pHbHIV4 con-
struct. The 3* splice sites of exons 4a, 4c, 4b, and 5
efficient (Fig. 7). The importance of a strong first 5* splice could not be separated since they are clustered within
site for viral replication is supported by the observation a 41-nt region; together they spliced at 48%. Splicing
of Purcell and Martin (1993) that mutation of this splice at the individual sites within this cluster must represent
site leads to activation of a cryptic site 4 nt downstream a fraction of the composite we have measured. It would
in a sequence highly conserved among HIV-1 isolates. be of interest to map the branchpoints involved in HIV-
Since all spliced HIV-1 mRNAs (both 4- and 2-kb classes) 1 RNA splicing, particularly those involving this cluster
use the first 5* splice site, it is not surprising that this is of four 3* splice sites. It is possible that some of these
a strong splice site; otherwise aberrantly spliced mRNAs splice sites may share branchpoints or pyrimidine
retaining the first intron might be generated. Further, the tracts. Temporal analysis of alternative splicing of the
presence of alternative weak 3* splice sites that pair with competing 3* splice sites in the transcripts encoding
a single strong 5* splice site allows multiple mRNAs to the regulatory proteins Tat and Rev revealed that the
be generated by competition between these 3* splice relative levels of these transcripts remained constant
sites. Work of Hammarskjold and coworkers (Hammar- throughout viral replication, suggesting that alternative
skjold et al., 1994; Lu et al., 1990) also suggests that the splicing was not being regulated by trans-acting viral
or cellular factors but by cis-acting splice site prefer-presence of an active 5* splice site may be necessary
FIG. 7. Comparison of splice site efficiencies for HIV-1 and RSV RNAs. (A) The average percentages of spliced RNAs from Table 2 are plotted
for the HIV-1 splice sites positioned on the HIV-1 RNA genome. (B) The average spliced RNA levels are plotted for RSV splice sites. Similar splice
site swapping experiments were performed in which the RSV splice sites were paired with the splice sites associated with the chicken c-myc
second intron (McNally and Beemon, 1992). The RSV major 5* splice site is 88% spliced, the env 3* splice site is 62% spliced, and the src 3* splice
site is 47% spliced; thus in both HIV-1 and RSV, the major 5* splice site was strong while the 3* splice sites were weaker.
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ences (Guatelli et al., 1990). The existence of variable gesting regulatory elements may not be present in the
vicinity of the strong, first 5* splice site of HIV-1 RNA.splice site efficiencies would be consistent with this.
Unlike the simple retroviruses, HIV-1 encodes a regu-In the avian retroviruses, splicing is regulated both by
latory protein, Rev, necessary for productive expressionsuboptimal splice sites and by cis-acting elements (Katz
of unspliced and partially spliced viral transcripts in theand Skalka, 1990; McNally and Beemon, 1992; Zhang
cytoplasm (Emerman et al., 1989; Felber et al., 1989;and Stoltzfus, 1995). In RSV, an intronic sequence in the
Hammarskjold et al., 1989; Malim et al., 1989). Multiplegag gene, the NRS, inhibits splicing (Arrigo and Beemon,
functions have been demonstrated for Rev including inhi-1988; Gontarek et al., 1993; McNally et al., 1991; Stoltzfus
bition of splicing (Felber et al., 1990; Kjems et al., 1992;and Fogarty, 1989). In this work, analysis of the gag–pol
Kjems and Sharp, 1993), increasing RNA stability (Fein-region of HIV-1 did not reveal sequences functionally
berg et al., 1986; Felber et al., 1989), nuclear export (Em-analogous to the NRS. The HIV-1 gag CRS element, IR-
erman et al., 1989; Felber et al., 1989; Hammarskjold et1, appeared initially to be an effective inhibitor of splicing
al., 1989; Malim et al., 1989; Fischer et al., 1994), andfrom the myc 5* splice site, but the inhibition observed
translation (Arrigo and Chen, 1991; Cochrane et al., 1991;was not from activity similar to that of the NRS but rather
D’Agostino et al., 1992) of RRE-containing transcripts. Revby competition between the HIV and the myc 5* splice
regulation of b globin constructs requires a single subop-sites. The sequences within the RSV NRS resemble both
timal splice site that delays intron removal, suggesting5* and 3* splice sites, and it has been shown that U1
that Rev may promote the disassociation of splicing com-and U2 snRNPs, as well as U11/U12 snRNPs, interact
plexes to allow transport of unspliced or incompletelywith the NRS (Gontarek et al., 1993). However, splicing
spliced RNA to the cytoplasm (Chang and Sharp, 1989).has never been observed into or out of the NRS in RSV
We have demonstrated that all HIV-1 introns are flankedconstructs, even when the authentic viral 3* splice sites
by at least one suboptimal splice site. Despite the pres-were deleted to relieve any potential competition (un-
ence of two efficient 5* splice sites, there were no pairspublished results). While it is possible that the methods
of efficient splice sites in HIV-1 because all the 3* spliceused here would not identify all negative elements, it
sites were suboptimal. This may be necessary to main-appears that elements capable of acting over a long
tain the high level of HIV-1 transcripts that remain un-distance, like the NRS, are not present in the gag – pol
spliced and to allow the use of all of the alternative 3*
region of HIV.
splice sites. In vitro studies have shown that a Rev pep-
While variation in efficiency of individual splice sites tide can inhibit splicing of RRE-containing transcripts
would contribute to the regulation of alternative splicing (Kjems et al., 1992; Kjems and Sharp, 1993); however,
in HIV-1, it does not preclude the existence of other levels this has not been observed with Rev-defective constructs
of regulation. Although we did not find an intronic, global, studied in vivo (Malim and Cullen, 1993). While Rev-medi-
cis-acting element in the gag or pol sequence of HIV-1, ated transport of RRE-containing RNA out of the nucleus
Amendt et al. (1994) identified a SRE within the first tat will prevent its further splicing, our studies show that
coding exon of HIV-1 that acted in a position- and orienta- splicing is inefficient even in the absence of Rev.
tion-dependent manner to inhibit splicing at the upstream
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